{
  "generated_at": "2026-01-23T22:14:24.974525",
  "public_days": 7,
  "summary": {
    "total_catalysts": 53,
    "this_week": 0,
    "next_week": 1,
    "this_month": 3,
    "by_type": {
      "PDUFA": 6,
      "Phase 3": 46,
      "Phase 2": 1,
      "AdCom": 0,
      "Other": 0
    }
  },
  "catalysts": [
    {
      "ticker": "XNCR",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 8,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 1010.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "RGNX",
      "date": "2026-02-08",
      "date_display": "Feb 08, 2026",
      "weekday": "Sunday",
      "days_until": 16,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FT",
          "label": "Fast Track",
          "color": "blue"
        },
        {
          "code": "PR",
          "label": "Priority Review",
          "color": "orange"
        },
        {
          "code": "AA",
          "label": "Accelerated Approval",
          "color": "yellow"
        },
        {
          "code": "RMAT",
          "label": "RMAT",
          "color": "teal"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 715.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": 65,
        "play_type": "Standard",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 89.3
      },
      "meta": {
        "has_position": true,
        "research_available": true
      }
    },
    {
      "ticker": "VNDA",
      "date": "2026-02-21",
      "date_display": "Feb 21, 2026",
      "weekday": "Saturday",
      "days_until": 29,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "company": {
        "mcap_millions": 456.0,
        "short_interest_pct": 7.88
      },
      "analysis": {
        "cont_score": 72,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": true,
        "research_available": true
      }
    },
    {
      "ticker": "GOSS",
      "date": "2026-02-28",
      "date_display": "Feb 28, 2026",
      "weekday": "Saturday",
      "days_until": 36,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data",
        "drug_name": "Seralutinib (GB002)",
        "indication": "Pulmonary Arterial Hypertension (PAH)"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 590.0,
        "short_interest_pct": 3.6
      },
      "analysis": {
        "cont_score": 60,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 96.4
      },
      "meta": {
        "has_position": true,
        "research_available": true
      }
    },
    {
      "ticker": "LNTH",
      "date": "2026-03-06",
      "date_display": "Mar 06, 2026",
      "weekday": "Friday",
      "days_until": 42,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "PYLARIFY (Piflufolastat F 18)",
        "indication": "PSMA PET Imaging Agent in Prostate cancer"
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "company": {
        "mcap_millions": 4340.0,
        "short_interest_pct": 8.89
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 96.4
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "IMMP",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 67,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Eftilagimod alfa (efti) + Keytruda",
        "indication": "Non-small cell lung carcinoma (1L NSCLC)"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FT",
          "label": "Fast Track",
          "color": "blue"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 447.46,
        "short_interest_pct": 3.59
      },
      "analysis": {
        "cont_score": 55,
        "play_type": "Standard",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 96.4
      },
      "meta": {
        "has_position": true,
        "research_available": true
      }
    },
    {
      "ticker": "ARQT",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 67,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "ZORYVE\u00ae (ARQ-151) topical roflumilast cream 0.05%",
        "indication": "Atopic dermatitis"
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 3498.0,
        "short_interest_pct": 22.16
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 96.4
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "TBPH",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 67,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Ampreloxetine (TD-9855)",
        "indication": "Multiple System Atrophy, Neurogenic orthostatic hypotension"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 965.0,
        "short_interest_pct": 9.7
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "AVBP",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 67,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        }
      ],
      "company": {
        "mcap_millions": 900.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "KPTI",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 67,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 145.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "KOD",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 67,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Tarcocimab (KSI-301) (anti-VEGF)",
        "indication": "Non-proliferative diabetic retinopathy"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 1650.0,
        "short_interest_pct": 21.9
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "KPTI",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 67,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "XPOVIO (Selinexor) (XPO1 inhibitor) + ruxolitinib",
        "indication": "Myelofibrosis"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FT",
          "label": "Fast Track",
          "color": "blue"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 115.54,
        "short_interest_pct": 19.0
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "ARGX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 67,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "VYVGART/Efgartigimod (ARGX-113) (FcRn Blocker)",
        "indication": "Ocular Myasthenia Gravis"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 49500.0,
        "short_interest_pct": 3.68
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 96.4
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "DNLI",
      "date": "2026-04-05",
      "date_display": "Apr 05, 2026",
      "weekday": "Sunday",
      "days_until": 72,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "DNL310 (tividenofusp alfa)",
        "indication": "Hunter syndrome MPS II"
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FT",
          "label": "Fast Track",
          "color": "blue"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "PR",
          "label": "Priority Review",
          "color": "orange"
        },
        {
          "code": "AA",
          "label": "Accelerated Approval",
          "color": "yellow"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 2540.0,
        "short_interest_pct": 4.5
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "MESO",
      "date": "2026-04-30",
      "date_display": "Apr 30, 2026",
      "weekday": "Thursday",
      "days_until": 97,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Update",
        "drug_name": "Rexlemestrocel",
        "indication": "Chronic lower back pain (CLBP)"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FT",
          "label": "Fast Track",
          "color": "blue"
        },
        {
          "code": "PR",
          "label": "Priority Review",
          "color": "orange"
        },
        {
          "code": "RMAT",
          "label": "RMAT",
          "color": "teal"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 2380.0,
        "short_interest_pct": 1.58
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "MNKD",
      "date": "2026-05-29",
      "date_display": "May 29, 2026",
      "weekday": "Friday",
      "days_until": 126,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 1650.0,
        "short_interest_pct": 8.6
      },
      "analysis": {
        "cont_score": 75,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": true,
        "research_available": true
      }
    },
    {
      "ticker": "ACHV",
      "date": "2026-06-20",
      "date_display": "Jun 20, 2026",
      "weekday": "Saturday",
      "days_until": 148,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Cytisinicline",
        "indication": "Smoking cessation"
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 290.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": 55,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 92.9
      },
      "meta": {
        "has_position": true,
        "research_available": true
      }
    },
    {
      "ticker": "CRMD",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 158,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "REZZAYO (rezafungin)",
        "indication": "Prophylaxis of Fungal Infections"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FT",
          "label": "Fast Track",
          "color": "blue"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 530.81,
        "short_interest_pct": 21.63
      },
      "analysis": {
        "cont_score": 90,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 62.5
      },
      "meta": {
        "has_position": true,
        "research_available": true
      }
    },
    {
      "ticker": "MIRM",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 158,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Interim Update",
        "drug_name": "Brelovitug (Monoclonal Antibody)",
        "indication": "Chronic Hepatitis Delta Virus (HDV)"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 4740.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 89.3
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "ARWR",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 158,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 9000.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "ATAI",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 158,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 1350.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "AVDL",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 158,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        }
      ],
      "company": {
        "mcap_millions": 2090.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "IPHA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 158,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 165.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "RNA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 158,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 10860.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "IONS",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 158,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Pelacarsen",
        "indication": "Heart disease, Cardiovascular disease"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 13250.0,
        "short_interest_pct": 6.59
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 92.9
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "LLY",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 158,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Taltz + Zepbound (Combination Therapy)",
        "indication": "Plaque Psoriasis With Obesity Or Overweight"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "company": {
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 0.0
      },
      "meta": {
        "has_position": false,
        "research_available": false
      }
    },
    {
      "ticker": "ARWR",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 204,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Plozasiran (ARO-APOC3)",
        "indication": "Severe hypertriglyceridemia"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FT",
          "label": "Fast Track",
          "color": "blue"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 9180.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 92.9
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "KPTI",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 204,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "XPOVIO (Selinexor) (XPO1 inhibitor)",
        "indication": "Endometrial cancer"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 115.5,
        "short_interest_pct": 16.7
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 89.3
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "KOD",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 250,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Tarcocimab (KSI-301) (anti-VEGF)",
        "indication": "Non-proliferative diabetic retinopathy"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 1500.0,
        "short_interest_pct": 21.9
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "AARD",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 250,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 335.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "GERN",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 250,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 830.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "GNLX",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 250,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 114.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "IMCR",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 250,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 1720.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "IVA",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 250,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 850.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "QNRX",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 250,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 16.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "RCUS",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 250,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 2350.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "RZLT",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 250,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 180.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "HRMY",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 342,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 TEMPO study data readout",
        "drug_name": "WAKIX\u00ae (pitolisant) ",
        "indication": "Muscle weakness, Muscle degeneration, Myotonic Dystrophy Type 1"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 2117.0,
        "short_interest_pct": 3.5
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 50.0
      },
      "meta": {
        "has_position": false,
        "research_available": false
      }
    },
    {
      "ticker": "CRVS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 342,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 1780.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "FGEN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 342,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        }
      ],
      "company": {
        "mcap_millions": 30.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "RVMD",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 342,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 22500.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "XFOR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 342,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 393.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "ZNTL",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 342,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 214.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "CRVS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 342,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Interim Update",
        "drug_name": "Soquelitinib (CPI-818)",
        "indication": "Peripheral T-cell Lymphomas"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "AA",
          "label": "Accelerated Approval",
          "color": "yellow"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 1910.0,
        "short_interest_pct": 10.34
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 82.1
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "BMY",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 342,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "KarXT (M1/M4 muscarinic agonist)",
        "indication": "Schizophrenia, Mental health, Alzheimers disease"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "company": {
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 0.0
      },
      "meta": {
        "has_position": false,
        "research_available": false
      }
    },
    {
      "ticker": "MRNA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 342,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "mRNA-4157/V940 +KEYTRUDA",
        "indication": "Cancer, Non-small cell lung carcinoma"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "company": {
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 0.0
      },
      "meta": {
        "has_position": false,
        "research_available": false
      }
    },
    {
      "ticker": "RARE",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 342,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "GTX-102",
        "indication": "Angelman Syndrome"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FT",
          "label": "Fast Track",
          "color": "blue"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 2277.0,
        "short_interest_pct": 9.24
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "SMMT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 342,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Ivonescimab (SMT112)",
        "indication": "1L Non-small cell lung carcinoma"
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FT",
          "label": "Fast Track",
          "color": "blue"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 14000.0,
        "short_interest_pct": 30.19
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "BLTE",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 523,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 6010.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "NBTX",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 523,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 1100.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "PROK",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 523,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 300.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "KRYS",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 707,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "company": {
        "mcap_millions": 8300.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    },
    {
      "ticker": "LXEO",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 707,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "company": {
        "mcap_millions": 550.0,
        "short_interest_pct": null
      },
      "analysis": {
        "cont_score": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true
      }
    }
  ]
}